Background
Phase 2, multicenter, single-arm trial (GIMEMA LAL2317). N=149 adults (ages 18–65, median 41) with newly diagnosed Philadelphia-negative, BCR::ABL1-negative CD19+ B-lineage ALL. Patients received an intensive GIMEMA (LAL1913) chemotherapy backbone plus two cycles of blinatumomab intercalated after chemotherapy cycles 3 and 6. Primary endpoint: increase in MRD negativity after blinatumomab cycle 1 among evaluable patients. Published Blood 2025.
Interventions and follow up
Regimen: Pediatric-inspired GIMEMA induction-consolidation with blinatumomab 28 µg/d continuous IV ×28 days intercalated after chemotherapy cycles 3 and 6, in Ph-negative CD19+ B-ALL
Primary endpoint: MRD negativity rate after blinatumomab cycle 1
Median follow-up: Not reported (NR) in the primary publication
Primary endpoint: MRD negativity rate after blinatumomab cycle 1
Median follow-up: Not reported (NR) in the primary publication
Results
MRD negativity (primary): Increased 72% → 93% after blinatumomab cycle 1, P<.001; 23/30 MRD-positive patients (73%) converted to MRD-negative
3-year OS (ITT, all 149): 78% overall; chemotherapy-managed 91%, allo-HSCT-allocated 59%, transplant recipients 69%
3-year relapse: Chemo arm 15%, allo-HSCT arm 35%, transplant recipients 19%
Blinatumomab exposure: 122/149 received blinatumomab; 109 had evaluable MRD before and after cycle 1
3-year OS (ITT, all 149): 78% overall; chemotherapy-managed 91%, allo-HSCT-allocated 59%, transplant recipients 69%
3-year relapse: Chemo arm 15%, allo-HSCT arm 35%, transplant recipients 19%
Blinatumomab exposure: 122/149 received blinatumomab; 109 had evaluable MRD before and after cycle 1
Adverse events
Blinatumomab-related: Grade ≥3 neurologic events ~15% (consistent with the established profile); cytokine release syndrome rare
Chemotherapy-related: Standard chemotherapy toxicities dominated the overall profile; no unexpected safety signals from sequential blinatumomab insertion
Chemotherapy-related: Standard chemotherapy toxicities dominated the overall profile; no unexpected safety signals from sequential blinatumomab insertion
Conclusions
Sequential insertion of blinatumomab into a standard GIMEMA chemotherapy backbone substantially increased MRD negativity (72% → 93%), with 73% of MRD-positive patients converting to MRD-negative. The 3-year OS of 91% for patients managed without allo-HSCT supports MRD-negative remission consolidation without transplantation in selected patients.
Key Limitations
Single-arm design with no randomized control, so the incremental benefit of blinatumomab over chemotherapy alone cannot be quantified. Survival comparisons between chemo-managed and transplant arms are confounded by selection (higher-risk, MRD-positive patients allocated to alloSCT). Modest sample (N=149) and follow-up not reported in the primary publication limit durability assessment. Generalizability beyond the GIMEMA backbone is uncertain.
Clinical Context
GIMEMA LAL2317 adds to the converging evidence (alongside ECOG E1910) that frontline blinatumomab consolidation deepens MRD response and improves outcomes in adult Ph-negative B-ALL. The high OS in MRD-negative, chemotherapy-only patients reinforces an emerging strategy of using MRD response to spare selected patients allo-HSCT, consistent with ESMO and ELN emphasis on MRD-directed therapy. The findings support incorporating blinatumomab into modern frontline ALL regimens.